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Abstract
Background: No satisfactory biomarkers are currently available to screen for nasopharyngeal
carcinoma (NPC). We have developed and evaluated surface-enhanced laser desorption/ionization
time-of-flight mass spectrometry (SELDI-TOF MS) for detection and analysis of multiple proteins
for distinguishing individuals with NPC from control individuals.
Methods: A preliminary learning set and a classification tree of spectra derived from 24 patients
with NPC and a group of 24 noncancer controls were used to develop a proteomic model that
discriminated cancer from noncancer effectively. Then, the validity of the classification tree was
challenged with a blind test set, which included another 20 patients with NPC and 12 noncancer
controls.
Results: A panel of 3 biomarkers ranging m/z 3–20 k was selected to establish Decision Tree
model by BPS with sensitivity of 91.66% and specificity of 95.83%. The ability to detect NPC
patients was evaluated, a sensitivity of 95.0% and specificity of 83.33% were validated in blind testing
set.
Conclusion: This high-flux proteomic classification system will provide a highly accurate and
innovative approach for the detection/diagnosis of NPC.
Background
Nasopharyngeal carcinoma (NPC) is a disease that has
remarkable racial and geographic distribution [1]. It is
rare in Europe and North America. However, it has a high
incidence in several southern areas in China, especially in
the provinces of Guangdong, Guangxi, Hunan and Hong
Kong Special Administrative Region et al [2]. The phe-
nomenon indicates that the development of this cancer
must be related to special genetic and environmental fac-
tors.
NPC is highly sensitive to radiotherapy (RT) and chemo-
therapy (CT), but the outcome is related to the extent of
the disease. Unfortunately, most patients with NPC are
diagnosed at stage III or IV NPC when they visit the
otorhinolaryngologists. Therefore, early detection and
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diagnosis of NPC is crucial for a better outcome of the
patients [3].
Routine clinical methods of examination for nasopharyn-
geal diseases, such as the use of nasoendoscopy, are not
applicable as a screening tool because can be used only by
an otorhinolaryngologist and are not cost effective.
Epstein-Barr virus (EBV) infection is consistently associ-
ated with NPC, and is classified as a group I carcinogen by
the International Agency for Research on Cancer (IARC)
[4,5]. Serological tests, detecting the antibodies to
Epstein-Barr virus (EBV), such as viral capsid antigen
(VCA) immunoglobulin A (IgA), early antigen (EA) IgA,
and Epstein-Barr nuclear antigen (EBNA1) IgA have been
used routinely as serological screening markers in high-
risk populations. Nevertheless, none of them has proven
to be a stand-alone and reliable assay due to either low
sensitivity or specificity [6,7]. Therefore, identification of
additional biomarkers is important for the early detection
and management of this disease.
The proteome reflect all proteins and peptides that may be
related with one gene and allows a more detailed evalua-
tion of disease status using the human proteome. At
present, it has become relatively easy to detect the protein
profiling in the crude biological samples with surface-
enhanced laser desorption/ionization-time of flight mass
spectrometry (SELDI-TOF MS). The proteomic technique
was first introduced by Hutchens and Yip in 1993 [8], and
applied to protein chips with different chromatographic
affinities in serum. This is a high-throughput technical
plateform which can detect multiple protein changes
simultaneously with high sensitivity and specificity
[9,10].
In the present study, by comparative analysis of patients
with NPC and noncancer controls, using Ciphergen
SELDI Software 3.1.1 with Biomarker Wizard, some
potential serum NPC-associated proteins biomarkers were
discovered, which might be new candidate biomarkers for
NPC diagnosis. At the same time, the diagnostic model
was established which could effectively differentiate NPC
patients from noncancer controls.
Methods
Study population
The serum samples of 80 patients collected between Octo-
ber 2007 and April 2008 were provided by First Affiliated
Hospital, Guangxi Medical University. The only selection
criterion for patients was that their NPC diagnosis had
been confirmed pathologically. The diagnosis of all
patients was poorly differentiated squamous cell carci-
noma. The control group comprised 36 noncancer nor-
mal volunteers who visited the General Health Check-up
Division at First Affiliated Hospital, Guangxi Medical Uni-
versity. Selection criteria for controls were no evidence of
any personal or family history of cancer or other serious
illness. All NPC patients and noncancer donors involved
in the study signed an agreement form consenting to the
donation of their specimens. The demographics of the
NPC patients and controls were shown in Table 1. From
each sample, 8 ml blood was allowed to clot at 4°C for at
least 2 h and then centrifuged at 1500 g for 10 min to sed-
iment the clotted cells. Serum was collected, divided into
aliquots, and stored frozen at -80°C until ProteinChip
array profiling analysis was carried out.
Serum Protein Profiling
Each serum sample was analyzed on four different Pro-
teinChip arrays surfaces: hydrophobic (H50), cation-
exchange (CM10), anion-exchange (Q10) and metal
binding (IMAC30-Cu). In addition, sinapinic acid (SPA)
was used as energy absorbing molecule (EAM) on all sur-
faces in parallel experiments. The CM10 chip was found
to attain the highest number of protein peaks among the
chips tested. Therefore, it was suitable for this work and
used throughout the study. Serum samples were thawed
and briefly centrifuged (5 minutes, 10,000 revolutions per
minute [rpm]) and pretreated before loading. To 10 μl of
each serum sample, 20 μl U9(5 μl of a solution containing
8 mol/L urea and 10 g/L CHAPS in 1×phosphate-buffered
saline(PBS) [pH 7.2])was added. The mixture was incu-
bated with vigorous shaking at 4°C for 30 minutes. After
incubation, the diluted serum mixture was mixed with
360 μl binding/washing buffer (0.1 M sodium acetate,
[pH 4.0]). Place the ProteinChip array cassette in the bio-
processor and add 200 μl binding solution to each well.
Incubate for 5 minutes at room temperature with vigorous
shaking (e.g., 250 rpm or on Micromix shaker setting 20/
7), Repeat once. Remove the buffer from the wells. Imme-
diately add 100 μl sample to each well. Incubate with vig-
orous shaking for 1 hour at room temperature. Remove
the samples from the wells, and wash each well with 200
μl binding buffer for 5 minutes, with agitation. Repeat
once. Remove the binding buffer from the wells, and add
200  μl HEPES (50 mM hydroxyethyl piperazine
ethanesulfonic acid, [pH4.0]) to each well; remove imme-
diately. Then, the ProteinChip was removed from the bio-
processor and dried at room temperature. Apply 1 μl of
SPA (sinapinic acid [Sigma Chemical, St. Louis, MO] in
50% acetonitrile volume/volume (v/v) and 0.5% v/v trif-
Table 1: Demographics of The Study Population
Groups stage Number Sex(M/F) MedianAge (Years)
NPC I&II 16 9/7 49
III & IV 28 18/10 53
Noncancer
Normal
36 15/21 45
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luoroacetic acid) Energy Absorbing Molecules (EAM) in
solution to each spot. Air-dry for 5 minutes and apply
another 1 μl of SPA in solution. Allow to air-dry.
SELDI-TOF MS Analysis
Mass/charge (m/z) spectra of proteins with affinity to the
Weak Cation Exchanger surface were generated in a
Ciphergen Protein Biology System (PBS-IIc) plus TOF-MS
Reader (Ciphergen Biosystems). Data were collected by
averaging the results of a total of 200 laser shots with an
intensity of 180, a detector sensitivity of 8, a high mass to
m/z 100 k and an optimization range of m/z 2–20 k. Mass
curacy was calibrated externally using the All-in-One pep-
tide mass standard (Ciphergen Biosystems) and SELDI-
TOF-MS analysis was performed on the same day.
Data Analysis
The entire dataset was randomly separated into training
and test datasets before analysis. A training set consisted
of spectra data from 24 patients with NPC and 24 noncan-
cer controls to build up the classification tree. The dis-
criminatory ability of the classification algorithm was
then challenged with a blind test dataset consisting of
another spectra data of another 32 serum samples. All
spectral data were normalized by total ion current after
background subtraction. The range of peak masses was
analyzed between m/z 2–20 k because the majority of
resolved protein/peptides were found in this range. The
molecular masses from m/z 0–2 k were excluded from
analysis because they were mainly the signal noises of the
energy absorbing molecule (EAM). The Biomarker Wizard
(Ciphergen Biosystems) was subsequently used to make
peak detection and clustering across all spectra in the
training set with the following settings: signal/noise (first
pass): 5; minimum peak threshold: 15% of all; mass error:
0.3%; and signal/noise (second pass): 2 for the m/z 2–20
k mass range. Corresponding peaks in the spectra from the
test set were likewise identified using the clustering data
from the training set by the same software. The spectral
data of the training set were then exported as spreadsheet
files and then further analyzed by the Biomarker Pattern
Software (BPS) (version 4.0; Ciphergen Biosystems) to
develop a classification tree.
Decision Tree Classification
One of the objectives of SELDI-TOF MS data analysis is to
build a Decision Tree that is able to determine the target
condition (case or control, cancer or non-cancer) for a
given patient's profile. Peak mass and intensity were
exported to an excel file, then transferred to BPS. The clas-
sification model was built up with BPS. A Decision Tree
was set up to divide the training dataset into either the
cancer group or the control group through multiple
rounds of decision-making. When the dataset was first
transferred to BPS, the dataset formed a "root node". The
software tried to find the best peak to separate this dataset
into two "child nodes" based on peak intensity. To
achieve this, the software would identify the best peak and
set a peak intensity threshold. If the peak intensity of a
blind sample was lower than or equal to the threshold,
this peak would go to the left-side child node. Otherwise,
the peak would go to the right-side child node. The proc-
ess would go on for each child node until a blind sample
entered a terminal node, either labeled as cancer or con-
trol. Peaks selected by the process to form the model were
the ones that yielded the least classification error when
these peaks were combined to be used. The double-blind
sample dataset was used to challenge the model. Peaks
from the blind dataset were selected with Biomarker Wiz-
ard feature of the Software, following the exact conditions
under which peaks from the training dataset were
selected. The peak intensities were then transferred to BPS,
and each sample was identified as either control or cancer
based on the model. The results were compared to clinical
data for model evaluation. To characterize the protein
peaks of potential interest, serum profiling of patients
with NPC and normal control was compared. Mean peak
intensity of each protein was calculated and compared
(nonparametric test) in each group of serum samples
[11].
Statistical analysis
Sensitivity was calculated as the ratio of the number of
correctly classified diseased samples to the total number
of diseased samples. Specificity was calculated as the ratio
of the number of negative samples correctly classified to
the total number of true negative samples.
Results
Reproducibility and precision
To assess the precision and accuracy of the proteomic data
in our analyses, we employed external calibration stand-
ards using all-in-one peptide molecular mass standard
(Ciphergen Biosystems, Inc. Ciphergen Biosystems, Inc.
USA), allowing us to achieve a mass accuracy of approxi-
mately 0.1%. To confirm the reproducibility of our analy-
ses, we compared 10 selected M/Z peaks from an
unaffected person. The coefficient of variance for the
selected M/Z peaks with the highest amplitude was less
than 15%.
Serum SELDI profiles of NPC versus nocancer normal 
controls
After noise filtering and peak cluster identification, 94
mass peaks were detected in the training set. These peak
data from the training set were saved and exported for pat-
tern recognition by the BPS. The most optimal Decision
Tree with the highest accuracy eventually was established.
The Decision Tree used 3 splitters with distinct masses of
m/z 3159.83 5187.65 13738.6 respectively, and classifiedJournal of Experimental & Clinical Cancer Research 2009, 28:85 http://www.jeccr.com/content/28/1/85
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the cases into 3 lymph nodes (Figure. 1). The peaks at m/
z 13738.6 were highly expressed in NPC but weakly
expressed in healthy individuals, and the other 2 peaks
were highly expressed in healthy individuals but weakly
expressed in patients with NPC. The descriptive statistics
of these 3 Biomarkers were shown in Table 2. Characteris-
tic spectrum graphs of 3 Biomarker were shown in Figure
2, Figure 3, and Figure 4 and the descriptive statistics are
shown in Figure 5.
The error rate of the generated Decision Tree was esti-
mated through a process of cross-validation. Performance
of the generated Decision Tree is summarized in Table 3
for the training and test sets. A blind test set, which con-
sisted of samples from 20 patients with cancer and 12
noncancer controls, was used to evaluate the ability of
Diagnostic Pattern to distinguish between patients with
NPC and noncancer controls. In our study, 10 of 12 true
noncancer control samples were classified correctly, and
19 of 20 cancer samples were classified correctly as malig-
nant. This set result yielded a sensitivity of 95%, a specifi-
city of 83.33%, and an accuracy rate of 90.63% (Table 3).
Discussion
Currently, there are no satisfactory serum diagnostic
markers for NPC, especially in the early stage [12]. Com-
plex serum proteomic patterns might reflect the potential
pathological state of a disease such as NPC and enable the
scientific community to develop more reliable diagnostic
tools. In this study, we used SELDI-TOF MS technology to
disclose the serum protein 'fingerprints' of NPC and
thereby establish a new diagnostic model for NPC.
SELDI-TOF MS allows the identification of large numbers
of potential biomarkers in a biological sample, based on
molecular weights and chemical characteristics. In essence
it provides high throughput screening for biomarkers, par-
ticularly when present in low abundance, avoiding the
limitations of antibody binding and of only analyzing
predetermined proteins. It is able, therefore, to identify
proteins not previously appreciated to be potentially val-
uable biomarkers. The technology has been applied to
serum and urine to identify disease specific biomarkers
[13]. However, the number of peaks that can be identified
by this approach does not cover the whole serum pro-
teome. This is related to several potential technical limita-
tions. A more complete proteome could be obtained by
depleting serum of the most abundant proteins, prelimi-
nary fractionation of serum before analysis by SELDI-TOF
MS, or by testing several different ProteinChip arrays.
However, these technical limitations are counterbalanced
by the high efficiency and ease of use of the system, which
makes SELDI-TOF MS a useful tool for clinical proteomics
[14].
The tumorigenesis of NPC is a complex, multistep process
that involves multiple genetic mutations [15]. In light of
the multifactorial nature of NPC, it is plausible that a
combination of multiple biomarkers will be necessary to
improve the diagnosis of NPC. Our study has identified
94 potential biomarkers and established a protein diag-
nostic pattern to distinguish NPC from noncancer con-
trols with a specificity of 95.83% and a sensitivity of
91.66%. The accuracy rate of this pattern was 93.75%.
Among the 3 biomarkers, the m/z with m/z 3159.835
5187.656 were down-regulated in the cancer group, and
the m/z with 13738.6 was up-regulated in the cancer
group. In the blind test, the sensitivity was 95.0% and the
specificity was 83.33%. These results suggest that this pat-
tern of biomarkers can be used for the early detection and
screening of NPC. Further research is needed to identify
the 3 unknown m/z protein species in the serum profiles
of our patients and to confirm our current findings in
larger cohorts of study samples.
All together, the SELDI-TOF MS ProteinChip technology
can demonstrate that biomarkers are present in patients
with NPC and help establish differential patterns with
high sensitivity and specificity. Done reproducibly in mul-
tiple laboratories and the analysis is amenable to simulta-
neous analysis of dozens or hundreds of samples. In
addition to the current work detailed here, similar results
Diagram of a decision tree for the classification of the  nasopharyngeal carcinoma (NPC) and noncancer samples in  the learning dataset Figure 1
Diagram of a decision tree for the classification of the 
nasopharyngeal carcinoma (NPC) and noncancer 
samples in the learning dataset. The circles indicated the 
primary nodes and the squares were the terminal nodes. The 
mass value in the root nodes was followed by the intensity 
value.Journal of Experimental & Clinical Cancer Research 2009, 28:85 http://www.jeccr.com/content/28/1/85
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SELDI analysis of serum for proteomic pattern in samples from patients with nasopharyngeal carcinoma (NPC) and in control  samples with mass spectra and gel view Figure 2
SELDI analysis of serum for proteomic pattern in samples from patients with nasopharyngeal carcinoma 
(NPC) and in control samples with mass spectra and gel view. The x-axis represents the molecular mass calculation 
(mass-to-change ratio [m/z]) and the y-axis represents the relative intensity. The mass spectrographic profiles reveal up-regula-
tion of the m/z 13738.6.
SELDI analysis of serum for proteomic pattern in samples from patients with nasopharyngeal carcinoma (NPC) and in control  samples with mass spectra and gel view Figure 3
SELDI analysis of serum for proteomic pattern in samples from patients with nasopharyngeal carcinoma 
(NPC) and in control samples with mass spectra and gel view. The x-axis represents the molecular mass calculation 
(mass-to-change ratio [m/z]) and the y-axis represents the relative intensity. The mass spectrographic profiles reveal peaks in 
NPC samples and down-regulation of the m/z 3159.835.Journal of Experimental & Clinical Cancer Research 2009, 28:85 http://www.jeccr.com/content/28/1/85
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SELDI analysis of serum for proteomic pattern in samples from patients with nasopharyngeal carcinoma (NPC) and in control  samples with mass spectra and gel view Figure 4
SELDI analysis of serum for proteomic pattern in samples from patients with nasopharyngeal carcinoma 
(NPC) and in control samples with mass spectra and gel view. The x-axis represents the molecular mass calculation 
(mass-to-change ratio [m/z]) and the y-axis represents the relative intensity. The mass spectrographic profiles reveal m/z 
5187.656 peaks.
Relative peak intensities of m/z 3159.835, 5187.656, 13738.6 protein masses in serum samples from patients with nasopharyn- geal carcinoma (NPC) compared with samples from the noncancer controls Figure 5
Relative peak intensities of m/z 3159.835, 5187.656, 13738.6 protein masses in serum samples from patients 
with nasopharyngeal carcinoma (NPC) compared with samples from the noncancer controls. Results are shown 
as box-and-whisker plots.Journal of Experimental & Clinical Cancer Research 2009, 28:85 http://www.jeccr.com/content/28/1/85
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have been demonstrated in another recent publication
[15-17] and techniques to further improve data quality for
robust peak identification have also been described [18].
These features establish SELDI analysis as a powerful
approach to proteomic analysis in population based stud-
ies, and hence the utility of this technology can be
exploited in all phases of the NPC studies.
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Table 2: Statistical Analysis of 3 Biomarkers for Screening 
Patients With Nasopharyngeal Carcinoma Versus Healthy 
Controls
Intensity, mean ± SD
Protein peaks, m/z Noncancer normal NPC P
3159.835 2.13 ± 1.44 1.22 ± 1.04 0.017728
5187.656* 2.00 ± 1.31 1.38 ± 0.60 0.094881
13738.6 0.86 ± 0.54 1.31 ± 0.60 0.002791
SD indicates standard deviation; m/z, mass-to-change ratio; NPC, 
nasopharyngeal carcinoma.
*The peak is necessary for Decision Tree although the P value > 0.05.
Table 3: Performance of the Decision Tree Analysis of NPC in 
Training Test and Blind test Sets
Sensitivity,% Specificity, % Accuracy rate, %
Training set 91.66(22/24) 95.83(23/24) 93.75(45/48)
Test set 87.5(21/24) 95.83(23/24) 91.67(44/48)
Blind test set 95.0(19/20) 83.33(10/12) 90.63(29/32)